Nicotine addiction and treatment

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 493-507

  Rose, Jed E ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Addiction; Cigarette smoking; Dependence; Tobacco

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CIGARETTE SMOKE; CLONIDINE; MECAMYLAMINE; NICOTINE; NICOTINE GUM;

ABSTINENCE; ADDICTION; AIRWAY; CIGARETTE SMOKING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SENSATION; SMOKING CESSATION; SYMPTOM; TRANSDERMAL DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

HUMANS; NICOTINE; PSYCHOTROPIC DRUGS; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0029935357     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.493     Document Type: Review

References (111)

1. US Dep. Health Hum. Serv. 1989. Reducing the Health Consequences of Smoking. 25 Years of Progress. A Report of the Surgeon General. Rockville, MD: Public Health Serv.
2. Cent. Dis. Control. 1993. Mortality trends for selected smoking-related cancers and breast cancer - United States, 1950-1990. Morbid Mortal. Wkly. Rep. 42:857, 863-67
3. US Dep. Health Hum. Serv. 1990. The Health Benefits of Smoking Cessation. A Report of the Surgeon General. Rockville, MD: Public Health Serv.
4. Cent. Dis. Control. 1993. Smoking cessation during previous year among adults - United States, 1990 and 1991. Morbid Mortal. Wkly. Rep. 42:504-7
5. Jarvik ME, Gritz ER. 1977. Nicotine and tobacco. In Psychopharmacology in the Practice of Medicine, ed. ME Jarvik, pp. 483-95. New York: Appleton-Century-Crofts
6. Russell MAH. 1988. Nicotine replacement: the role of blood nicotine levels, their rate of change, and nicotine tolerance. See Ref. 110, pp. 63-94
7. US Dep. Health Hum. Serv. 1988. The Health Consequences of Smoking: Nicotine Addiction. Rockville, MD: Off. Smoking Health
8. Rose JE, Jarvik ME, Ananda S. 1984. Nicotine preference increases after cigarette deprivation. Pharmacol. Biochem. Behav. 20:55-58
9. Rose JE, Sampson A, Levin ED, Henningfield JE. 1989. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol. Biochem. Behav. 32:933-38
10. Corrigall WA, Coen KM. 1989. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-78
11. Henningfield J, Miyasato K, Jasinski D. 1983. Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav. 19:887-90
12. Gilbert DG. 1979. Paradoxical tranquilizing and emotion-reducing effects of nicotine. Psychol. Bull. 86:643-61
13. Jarvik ME. 1991. Beneficial effects of nicotine. Br. J. Addict. 86:571-76
14. Stitzer ML, Gross J. 1988. Smoking relapse: the role of pharmacological and behavioral factors. See Ref. 110, pp. 163-86
15. Warburton DM. 1992. Nicotine as a cognitive enhancer. Prog. Neuropsychopharmacol. Biol. Psychiatr. 16:181-91
16. Hughes JR, Gust SW, Skoog K, et al. 1991. Symptoms of tobacco withdrawal: A replication and extension. Arch. Gen. Psychol. 48:52-59
17. Levin ED, Briggs SJ, Christopher NC, Rose JE. 1993. Chronic nicotinic stimulation and blockade effects on working memory. Behav. Pharmacol. 4:179-82
18. Levin ED, Rose JE. 1991. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Br. Res. Bull. 27:125-28
19. Benowitz NL, Porchet H, Jacob PI. 1990. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. See Ref. 111, pp. 112-57
20. Henningfield JE, Stapleton JM, Benowitz NL, et al. 1993. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 33: 23-29
21. Wonnacott S. 1990. Characterization of nicotine receptor sites in the brain. See Ref. 111, pp. 226-77
22. Clarke PBS. 1990. The central pharmacology of nicotine: electrophysiological approaches. See Ref. 111. pp. 158-93
23. Collins AC, Evans CB, Miner LL, Marks MJ. 1986. Mecamylamine blockade of nicotine responses: evidence for two brain nicotinic receptors. Pharmacol. Biochem. Behav. 24:1767-73
24. Reavill C. 1990. Action of nicotine on dopamine pathways and implications for Parkinson's disease. See Ref. 111, pp. 307-40
25. Corrigall WA. 1995. Self-administered nicotine acts through the ventral tegmental area: implications for drug reinforcement mechanisms. In Effects of Nicotine on BiologialSystems II, ed. PBS Clarke, M Quik, F Adlkofer, K Thurau, pp. 203-9. Basel: Birkhauser Verlag
26. Dawe S, Gerada C, Russell MAH, Gray JA. 1995. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology 117:115
27. Jarvik ME, Caskey NH, Wirshing WC. 1995. Dopaminergic modulation of cigarette smoking. Presented at Soc. Res. Nicotine Tobacco, San Diego, CA
28. McEvoy JP, Freudenreich O, Levin ED, Rose JE. 1995. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119:124-26
29. McMorrow MJ, Foxx RM. 1983. Nicotine's role in smoking: an analysis of nicotine regulation. Psychol. Bull. 93:302-27
30. Russell MAH. 1987. Nicotine intake and its regulation by smokers. In Tobacco Smoking and Nicotine: A Neurobiological Approach, ed. WR Martin, GR Van Loon, ET Iwamoto, KD Davis, pp.25-50. New York: Plenum
31. Henningfield JE, Griffiths RR. 1980. Effects of ventilated cigarette holders on cigarette smoking by humans. Psychopharmacology 68:115-19
32. Herning RI, Jones RT, Bachman J, Mines AH. 1981. Puff volume increases when low-nicotine cigarettes are smoked. Br. Med. J. 283:187-89
33. Nil R, Battig K. 1989. Separate effects of cigarette smoke yield and smoke taste on smoking behavior. Psychopharmacology 99:54-59
34. Foulds J, Stapleton J, Feyerabend C, et al. 1992. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology 106:421-27
35. Jarvik ME, Glick SD, Nakamura RK. 1970. Inhibition of cigarette smoking by orally administered nicotine. Clin. Pharmacol. Ther. 11:574-76
36. Lucchesi BR, Schuster CR, Emley GS. 1967. The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid. Clin. Pharmacol. Ther. 8:789-96
37. Benowitz NL, Jacob P. 1990. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J. Pharmacol. Exp. Ther. 254:1000-5
38. Perkins KA, Grobe JE, Stiller RL, et al. 1992. Goettler JE. Nasal spray nicotine replacement suppresses cigarette smoking desire and behavior. Clin. Pharmacol. Ther. 52:627-34
39. Pomerleau OF, Flessland KA, Pomerleau CS, Hariharan M. 1992. Controlled dosing of nicotine via an intranasal aerosol delivery device (INADD). Psychopharmacology 108:519-26
40. Sutherland G, Stapleton JA, Russell MAH, et al. 1992. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324-29
41. Henningfield J, Goldberg S. 1983. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 19:1021-26
42. Fagerström KO. 1988. Efficacy of nicotine chewing gum: a review. See Ref. 110, pp. 109-28
43. Hughes JR, Glaser M. 1993. Transdermal nicotine for smoking cessation. J. Health Behav. Educ. Promot. 17:25-31
44. Palmer KJ, Buckley MM, Faulds D. 1992. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic effficacy as an aid to smoking cessation. Drugs 44: 498-529
45. Abelin T, Muller P, Buehler A, et al. 1989. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1: 7-10
46. Rose JE, Levin ED, Behm FM, et al. 1990. Transdermal nicotine facilitates smoking cessation. Clin. Pharmacol. Ther. 47: 323-30
47. Rose JE, Behm FM, Westman EC, et al. 1994. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:86-99
48. Rose JE. 1988. The role of upper airway stimulation in smoking. See Ref. 110, pp. 95-106
49. Rose JE, Levin ED. 1991. Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br. J. Addict. 86:605-10
50. Westman EC, Behm FM, Rose JE. 1995. Airway sensory replacement combined with nicotine replacement for smoking cessation: a randomized, placebo controlled trial using a citric acid inhaler. Chest 107: 1358-64
51. Rose JE, Behm FM, Levine ED. 1993. The role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol. Biochem. Behav. 44:891-900
52. Hasenfratz M, Baldinger B, Battig K. 1993. Nicotine or tar titration in cigarette smoking behavior? Psychopharmacology 112: 253-58
53. Hughes JR, Gulliver SB, Fenwick JW, et al. 1992. Smoking cessation among self-quitters. Health Psychol. 11:331-34
54. Gritz E, Marcus A, Carr C. 1988. Unaided smoking cessation: great American smokeout and New Year's Eve quitters. J. Psychosoc. Oncol. 6:217-34
55. Hirsch A, Slama K, Alberisio A, et al. 1994. Smoking cessation recommendations: recommendations for health professionals. Advisory Group of the European School of Oncology. Eur. J. Cancer 30A: 253-63
56. Hughes JR. 1995. Combining behavioral therapy and pharmacotherapy for smoking cessation: an update. In Integrating Behavior Therapies with Medication in the Treatment of Drug Dependence, ed. LS Onken, JD Blaine, JJ Boren, pp. 92-109. NI-DARes. Monogr. Washington, DC: US GPO
57. Pomerleau OF, Pomerleau CS. 1988. Introduction. In Nicotine Replacement: A Critical Evaluation, ed. OF Pomerleau, CS Pomerleau, New York: Liss
58. Shiftman SM, Jarvik ME. 1976. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50:35-39
59. Am. Psychiatr. Assoc. 1994. Diagnostic and Statistical Manual of Mental Disorders, ed. DSM-IV Task Force. Washington, DC: Am. Psychiatric Assoc. 4th ed.
60. Sachs DPL. 1995. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch. Intern. Med. 155:1-8
61. Tonnesen P, Norregard J, Mikkelsen K, et al. 1993. A double-blind trial of a nicotine inhaler for smoking cesation. JAMA 269: 1268-71
62. Rose JE, Jarvik ME, Rose KD. 1984. Transdermal administration of nicotine. Drug Alcohol Depend. 13:209-13
63. Rose JE, Herskovic JE, Trilling Y, Jarvik ME. 1985. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin. Pharmacol. Ther. 38:450-56
64. Daughton DM, Heatley SA, Prendergast JJ, et al. 1991. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch. Intern. Med. 151:749-52
65. Sachs DPL, Sawe U, Leischow SJ. 1993. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch. Intern. Med. 153:1881-90
66. Westman EC, Levin ED, Rose JE. 1993. The nicotine patch in smoking cessation: a randomized trial with telephone counseling. Arch. Intern. Med. 153:1917-23
67. Eichelberg D, Stolze P, Block M, Buchkremer G. 1989. Contact allergies induced by Its-treatment. Methods Find Exp. Clin. Pharmacol. 11:223-25
68. Hughes JR, Hatsukami DK, Pickens RW, et al. 1984. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83:82-87
69. Tonnesen P, Fryd V, Hansen M, et al. 1988. Two and four mg nicotine chewing gum and group counseling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict. Behav. 13:17-27
70. Gourlay SG, Forbes A, Marriner T, et al. 1994. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. Br. Med. J. 309: 842-46
71. Hymowitz N, Sexton M, Ockene J, Grandits G. 1991. Baseline factors associated with smoking cessation and relapse, Prev. Med. 20:590-601
72. Norregaard J, Tonnesen P, Petersen L. 1993. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev. Med. 22:261-71
73. Fagerström KO. 1978. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict. Behav. 3:235-41
74. Fagerström KO, Scheider NG. 1989. Measuring nicotine dependence: a review of the Fagerström tolerance questionaire. J. Behav. Med. 12:159-82
75. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. 1991. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionaire. Br. J. Addict. 86:1119-27
76. Pomerleau CS, Carton SM, Lutzke ML, et al. 1994. Reliability of the Fagerström tolerance questionnaire and the Fagerström test for nicotine dependence. Addict. Behav. 19: 101-6
77. Tate JC, Schmitz JM. 1993. A proposed revision of Fagerström tolerance questionnaire. Addict. Behav. 18:135-43
78. Kozlowski LT, Porter CQ, Orleans CT, et al. 1994. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 34:211-16
79. Russell MAH, Stapleton JA, Feyerabend C, et al. 1993. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. Br. Med. J. 306:1308-12
80. Kenford SL, Fiore MC, Jorenby DE, et al. 1994. Predicting smoking cessation. JAMA 271:589-91
81. Hjalmarson A, Franzon M, Westin A, Wiklund O. 1994. Effect of nicotine nasal spray on smoking cessation. Arch. Intern. Med. 154:2567-72
82. Hajek P, Jarvis MJ, Belcher MN, et al. 1989. Effect of smoke-free cigarettes on 24-h cigarette withdrawal: a double-blind placebo-controlled study. Psychopharmacology 97:99-102
83. Leischow SJ. 1994. The nicotine vaporizer. Health Values 18:4-9
84. Fagerström KO. 1994. Combined use of nicotine replacement products. Health Values 18:15-20
85. Fagerström KO, Schneider NG, Lunell E. 1993. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 111: 271-77
86. Sachs DPL, Benowitz NL, Bostrom AG, Hansen MD. 1994. Validity of the Sachs Optimum Dosing Algorithm (SODA) for determining nicotine patch dose to optimize tobacco dependence treatment. Presented at Annu. Meet. College Problems Drug Dependence, Palm Beach, FL, June 21
87. Clarke PBS. 1991. Nicotinic receptor blockade therapy and smoking cessation. Br. J. Addict. 86:501-5
88. Martin BR, Onaivi ES, Martin TJ. 1989. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol. 38:3391-97
89. Stolerman IP. 1986. Could nicotine antagonists be used in smoking cessation? Br. J. Addict. 81:47-53
90. Rose JE, Levin ED. 1991. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol. Biochem. Behav. 41:219-26
91. Rose JE, Behm FM, Westman EC, et al. 1994. Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction. Exp. Clin. Psychopharmacol. 2: 1-17
92. Spring B, Pingitore R, Kessler K. 1992. Strategies to minimize weight-gain after smoking cessation: psychological and pharmacological intervention with specifc reference to dexfenfluramine. Int. J. Obes. 16(Suppl. 3):S19-23
93. Deleted in proof
94. Pomerleau OF, Pomerleau CS, Morrell EM, Lowenbergh JM. 1991. Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology 16:433-40
95. Hilleman DE, Mohiuddin SM, Del Core MG, Sketch MH. 1992. Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch. Intern. Med. 152: 350-52
96. Hilleman DE, Mihiuddin SM, Delcore MG. 1994. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. J. Clin. Pharmacol. 34: 222-24
97. West R, Hajek P, McNeill A. 1990. Effect of buspirone on cigarette withdrawal symptons and short-term abstinence rates in a smokers clinic. Psychopharmacology 104: 91-96
98. Cinciripini PM, Lapitsky L, Seay S, et al. 1995. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J. Clin. Psychopharmacol. 15:182-91
99. Edwards NB, Murphy JK, Downs AD, et al. 1989. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am. J. Psychiatr. 146:373-76
100. Ferry LH, Burchette RJ. 1994. Efficacy of buproprion for smoking cessation in non-depressed smokers. J. Addict. Dis. 13: A9
101. Ornish SA, Zisook S, McAdams LA. 1988. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. Arch. Intern. Med. 148: 2027-31
102. Classman AH, Jackson WK, Walsh BT, et al. 1984. Cigarette craving, smoking withdrawal, and clonidine. Science 226:864-66
103. Prochazka AV, Petty TL, Nett L, et al. 1992. Transdermal clonidine reduced some withdrawal symptons but did not increase smoking cessation. Arch. Intern. Med. 152: 2065-69
104. Franks P, Hasrp J, Bell B. 1989. Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 262:3011-13
105. Behm FM, Schur C, Levin ED, et al. 1993. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug Alcohol Depend. 31:131-38
106. Behm FM, Rose JE. 1994. Reducing craving for cigarettes while decreasing smoke intake using capsaicin-enhanced low-tar-cigarettes. Exp. Clin. Psychopharmacol. 2: 143-53
107. Levin ED, Behm FM, Carnahan E, et al. 1993. Clinical trials using ascorbic acid aerosol to aid smoking cessation. Drug Alcohol Depend. 33:211-23
108. Rose JE, Hickman CS. 1987. Citric acid aerosol as a potential smoking cessation aid. Chest 92:1005-8
109. Rose JE, Behm FM. 1994. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug Alcohol Depend. 34:225-29
110. Pomerleau OF, Pomerleau CS, eds. 1988. Nicotine Replacement: A Critical Evaluation, Vol. 261. New York: Liss
111. Wonnacott S, Russell MAH, Stolerman IP, eds. 1990. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects. New York: Oxford Univ. Press